Yes, PrEP is for women. It is FDA-approved, clinically proven, and recommended for any woman at risk of HIV infection. Despite early research focusing heavily on men who have sex with men, large clinical trials have now confirmed PrEP’s effectiveness specifically in cisgender women, and multiple formulations are available. Yet PrEP remains dramatically underused by women, partly because many don’t realize they’re candidates for it.
How Well PrEP Works for Women
Women have two main PrEP options: a daily oral pill and a long-acting injectable. Both are highly effective when used consistently, but they work slightly differently in the body depending on the type of exposure.
The daily oral pill (a combination of tenofovir disoproxil fumarate and emtricitabine, sold as Truvada and generics) provides strong protection for vaginal sex when taken every day. One important distinction: PrEP medication absorbs more slowly into vaginal tissue than into rectal tissue. This means the “2-1-1” on-demand dosing strategy, where you take pills only around the time of sex, is not effective or recommended for women. Daily dosing is essential.
The injectable option, cabotegravir (Apretude), performed exceptionally well in the HPTN 084 trial, a large study conducted among women in sub-Saharan Africa. Women receiving the injection had an 88% lower risk of HIV compared to women taking the daily oral pill. After accounting for infections that likely occurred before the study drug took effect, that figure rose to 91%. The injection schedule starts with a dose at your first visit, a second dose four weeks later, then one injection every eight weeks after that.
A third oral option, a pill combining tenofovir alafenamide and emtricitabine (Descovy), is not approved for preventing HIV through receptive vaginal sex. It was only studied in men and transgender women, so it should not be used by cisgender women for PrEP.
Who Should Consider PrEP
PrEP is appropriate for any HIV-negative woman with factors that increase her chance of exposure. Clinical guidelines list several indicators of substantial risk: having a sexual partner who is HIV-positive, a recent sexually transmitted infection like syphilis or gonorrhea, multiple sex partners, inconsistent or no condom use, engaging in sex work, or living in an area with high HIV prevalence.
The formal criteria also describe women who are not in a monogamous relationship with a recently tested, HIV-negative partner and who have one or more additional risk factors. However, researchers have pointed out that these guidelines may actually disqualify many women who are genuinely at risk and motivated to use PrEP. Risk doesn’t always fit neatly into a checklist. If you’re concerned about HIV exposure for any reason, it’s a conversation worth having with a provider.
PrEP During Pregnancy and Breastfeeding
Pregnancy actually increases the chance of acquiring HIV, making prevention especially important during this time. The CDC considers the daily oral pill (TDF/FTC) generally safe for people who are pregnant or breastfeeding, and current perinatal guidelines specifically recommend it for women who may become pregnant, are pregnant, or are nursing.
If you become pregnant while already taking oral PrEP, you can continue it throughout pregnancy and breastfeeding. The available evidence suggests the benefits of preventing HIV outweigh potential risks to the fetus or infant. An Antiretroviral Pregnancy Registry tracks outcomes to provide early warning of any adverse effects.
The injectable form has less safety data during pregnancy. It can be started or continued in women who may become pregnant, but that decision involves weighing benefits against the limited information available. Because cabotegravir has a long half-life and stays in the body for an extended period after injection, this is worth discussing with your provider before starting.
PrEP and Birth Control
Oral PrEP does not interfere with hormonal contraceptives. The class of drugs used in PrEP (nucleoside reverse transcriptase inhibitors) shows no effect on combined hormonal contraceptives, progestin-only pills, implants, hormonal IUDs, or injectable contraceptives. The CDC classifies these combinations as having no restrictions or benefits generally outweighing risks. You can use PrEP alongside whatever birth control method you prefer without worrying about reduced effectiveness of either medication.
What to Expect on PrEP
Starting PrEP involves an HIV test to confirm you’re negative, along with baseline lab work. If you’re taking the oral pill, you’ll need follow-up visits that include repeat HIV testing, screening for sexually transmitted infections, and kidney function checks, since the medication can occasionally affect the kidneys. These visits typically happen every three months.
Common side effects of the oral pill tend to be mild: nausea, headache, or slight stomach upset, usually resolving within the first few weeks. For the injectable, injection site reactions like pain or tenderness at the injection site are the most frequently reported side effect. In the HPTN 084 trial, injection coverage remained high at 93% of total follow-up time, suggesting most women found the side effects manageable enough to continue.
Cost and Insurance Coverage
Under the Affordable Care Act, PrEP is classified as a preventive service, which means most health insurance plans must cover it with no out-of-pocket costs. This includes the medication itself, clinic visits, and all required lab tests, even if you haven’t met your deductible. This applies to employer-sponsored plans, marketplace plans, and Medicaid expansion coverage.
Medicare Part B now covers PrEP with no cost-sharing, including both oral and injectable options plus related counseling and screenings. Veterans can access PrEP through VA healthcare, and Indian Health Service centers provide it at no charge.
If you’re uninsured, drug manufacturers offer patient assistance programs that provide PrEP medication at no cost. If you have insurance but still face copays, manufacturer copay assistance programs and state-level PrEP assistance programs (currently available in California, Colorado, the District of Columbia, Illinois, Indiana, Iowa, Massachusetts, New Mexico, New York, Oklahoma, Virginia, and Washington) can help eliminate remaining costs for medication, lab work, and clinic visits.